LEADERSHIP TEAM

Our global team of medical and business experts are actively collaborating to develop innovative genetic tests, tools, and therapies. The possibilities of our genetic horizon are only going to continue to grow.

Management Team

dna

Gene Lee

Founder and Chairman

Gene is the Founder, Chairman of the board of directors and visionary behind the Avellino Labs network of companies. A serial entrepreneur, he started Avellino Labs in 2008 in South Korea and brings more than 20 years of experience leading pharmaceutical, healthcare, and genetic diagnostics teams. In 2013, Gene relocated to Silicon Valley to support Avellino Labs’ transition to a US-based global company. Gene is also the lead inventor and author of most of the patents in Avellino’s IP portfolio. In 2015, the World Economic Forum recognized Avellino Labs as a Technology Pioneer and honored Gene with membership on its Global Precision Medicine Council. Gene was awarded the Ellis Island Medal of Honor for his pioneering work in gene therapy and molecular diagnostics at a ceremony on Ellis Island on May 11, 2019.
dna

Jon Robson

President and CEO

As Avellino’s President, CEO and member of the Board of Directors, Jon Robson brings to the company his highly relevant experience in creating value from data and analytics with both early-stage technology companies and large multinational data businesses. He was the founder and CEO of MoneyLine Telerate, CEO of Reuters Americas, President of Thomson Reuters Enterprise Division, CEO of NYSE Technologies, President of First Derivatives plc, and President of DXC Luxoft’s Capital Markets division.
dna

Thomas Kim

Chief Strategy Officer and Corporate Secretary

Tom is the current Chief Strategy Officer and Corporate Secretary. Tom was Avellino Labs’ outside legal counsel from the incorporation of Avellino Labs USA office in 2011. He later became a consultant to the Board of Directors in 2015, then became a member of the Board of Directors of Avellino Labs in 2016, ultimately becoming the Chief Strategy Officer & Corporate Secretary in 2018. Tom brings his extensive legal and business experience in transactions involving venture capital financings, initial public offerings of securities, mergers and acquisitions, executive compensation law, and other strategic business transactions. Tom is one of the 2 founding partners of Kastner|Kim LLP. Prior to the formation of Kastner|Kim LLP, Tom was an attorney with Fenwick & West LLP in Silicon Valley.
dna

Laiq Ahmad

Chief Technology Officer

Laiq Ahmad is Avellino’s Chief Technology Officer, bringing more than 22 years of experience to the role. Laiq has advanced knowledge of digital transformation, cloud technologies, big data, AI, and machine learning. He leads the technology, engineering and innovation engine for the company’s next-generation sequencing applications and platforms, drives technology breakthroughs, and supports Avellino’s growth and innovation. He most recently was CTO – GE Power Digital/VP & Global Head for Digital Platform Engineering for GE Digital. In this role he was responsible for building and managing innovative industrial software platforms and led global engineering and technology teams, including groups supporting product vision, strategy and innovation, architecture and engineering, data science and advance analytics. Laiq holds a ALM from Harvard University, a Master’s Degree in Computer Science from Boston University, an MBA from Bundelkhand University, and a graduate certificate in Systems Engineering and Product Development from MIT.
dna

Cyril Allouche, MBA, CPA

Chief Financial Officer & Treasurer

Avellino also welcomes Cyril Allouche to the executive team as its new Chief Financial Officer and Treasurer. Mr. Allouche brings to Avellino over 20 years of experience in finance leadership in both public and pre-IPO companies, including diagnostics and biopharmaceutical. He most recently served as CFO at Dermavant Sciences and held finance leadership roles at Revance Therapeuthics and CareDx. He also spent over a decade at PricewaterhouseCoopers in Audit and Transaction services.
dna

Nazneen Aziz, PhD

Chief Scientific Officer

Dr. Aziz joins us after an impressive career at renowned health care institutions and educational centers such as Kaiser Permanente, the College of American Pathologists, Harvard Medical School/Boston Children’s Hospital, and Tufts University. She received her degrees from Wellesley and MIT, and has received multiple awards from MIT, National Institutes of Health, National Kidney Foundation, Cancer Research Institute, College of American Pathologists, St. Baldrick’s Foundation, Wellesley College, Kaiser Permanente Precision Medicine and the Garfield Memorial Fund. With 15 patents and over 50 oft-cited publications, she has lectured and collaborated in research projects around the world as an expert in genomics.
dna

Eric Bernabei

Global Head of Business & Corporate Development

Eric joins Avellino Labs from Alcon, bringing 20 years of product development and commercialization experience in the ophthalmic surgical industry. Eric started his career in patient care and moved into industry in 1999 with Summit Technology, one of the first excimer laser manufacturers. He continued to develop and take commercial leadership positions within Summit, BD Ophthalmic Systems, and then Alcon. He has focused on introducing new and advanced technologies most of his career in global, regional, and country level roles while based in the Americas, Asia/Japan, and most recently, the Europe, Middle East, and Africa region.
dna

Joe Boyd

Global Head of Sales and Marketing

Joe joins Avellino from Novartis, where he led the Market Development organization to record growth for their dry eye product, Xiidra. Joe has over 20 years of experience and played key roles in Large, Mid-Size, and Start-up companies in the diagnostic, pharmaceutical and medical device industries. Prior to Novartis, Joe successfully built and led teams at Shire, Takeda and Primus. He is frequently asked to speak as an Industry Expert to colleagues and professional associations about his experiences and successful strategies in leading Sales & Marketing, Compliance & Ethics, as well as, his experience leading Professional Affairs, Thought Leader Advocacy, Medical Affairs, Medical Communications, Competitive Intelligence, Commercial Operations, and Ethics & Compliance affecting both the companies and industries in which he has operated and excelled. His therapeutic fields of experience range from ophthalmology, oncology, urology, anti-infective, anti-inflammatory, allergy, asthma, dermatology, gastrointestinal, pulmonary endoscopy and biliary endoscopy.
dna

John Hong

Global Head of Operations

John brings over 12 years of HR, employment, and labor law experience to Avellino. John’s roles at Avellino include the development of HR/business/privacy/legal policies and processes, training, people/workforce development, business strategies, workforce plans, talent acquisition, and programs that align with the organization’s overall strategic growth. Prior to joining Avellino, John was a shareholder at the world’s largest labor & employment law firm, Littler Mendelson, where Avellino was his client. John received his JD from the University of San Francisco, BA in Economics and Spanish from Davidson College, and is SHRM-SCP certified.

Board of Directors

dna

Gene Lee

Founder and Chairman

Gene is the Founder, Chairman of the board of directors and visionary behind the Avellino Labs network of companies. A serial entrepreneur, he started Avellino Labs in 2008 in South Korea and brings more than 20 years of experience leading pharmaceutical, healthcare, and genetic diagnostics teams. In 2013, Gene relocated to Silicon Valley to support Avellino Labs’ transition to a US-based global company. Gene is also the lead inventor and author of most of the patents in Avellino’s IP portfolio. In 2015, the World Economic Forum recognized Avellino Labs as a Technology Pioneer and honored Gene with membership on its Global Precision Medicine Council. Gene was awarded the Ellis Island Medal of Honor for his pioneering work in gene therapy and molecular diagnostics at a ceremony on Ellis Island on May 11, 2019.
dna

Jon Robson

President and CEO

As Avellino’s President, CEO and member of the Board of Directors, Jon Robson brings to the company his highly relevant experience in creating value from data and analytics with both early-stage technology companies and large multinational data businesses. He was the founder and CEO of MoneyLine Telerate, CEO of Reuters Americas, President of Thomson Reuters Enterprise Division, CEO of NYSE Technologies, President of First Derivatives plc, and President of DXC Luxoft’s Capital Markets division.
dna

Thomas Kim

Chief Strategy Officer and Corporate Secretary

Tom is the current Chief Strategy Officer and Corporate Secretary. Tom was Avellino Labs’ outside legal counsel from the incorporation of Avellino Labs USA office in 2011. He later became a consultant to the Board of Directors in 2015, then became a member of the Board of Directors of Avellino Labs in 2016, ultimately becoming the Chief Strategy Officer & Corporate Secretary in 2018. Tom brings his extensive legal and business experience in transactions involving venture capital financings, initial public offerings of securities, mergers and acquisitions, executive compensation law, and other strategic business transactions. Tom is one of the 2 founding partners of Kastner|Kim LLP. Prior to the formation of Kastner|Kim LLP, Tom was an attorney with Fenwick & West LLP in Silicon Valley.
dna

Sang Yup Lee

Member of the Board of Directors

Dr Lee is Distinguished Professor at the Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST). He is currently the Dean of KAIST Institutes, Director of BioProcess Engineering Research Center, and Director of Bioinformatics Research Center. He served as a Founding Dean of College of Life Science and Bioengineering. Dr Lee is a pioneer of systems metabolic engineering, one of the Top 10 Emerging Technologies by World Economic Forum 2016, developing microbial bioprocesses to produce the world’s first engineered plastic raw materials and gasoline as well as artificial spider silk stronger than steel. He also developed DeepDDI, the AI deep learning framework that accurately predicts drug-drug and drug-food interactions, and the virtual cell model to accurately predict cancer cell metabolism and enable precision medicine treatment. He has published more than 580 journal papers, 82 books/book chapters, and more than 630 patents, many of which he licensed. He received numerous awards, including the National Order of Merit, National Science Medal, and he is the first Asian scientist to receive James Bailey Award and Marvin Johnson Award. He is editor-in-chief of Biotechnology Journal (Wiley) and Metabolic Engineering (Elsevier), and an editor and editorial board member of 30 international journals. He is a member of the Global Future Council on the Fourth Industrial Revolution, World Economic Forum, and he served as a member of the Presidential Advisory Council on Science and Technology of Korea, Government Performance Evaluation Committee. His research areas are metabolic engineering, systems biology, synthetic biology, systems medicine, industrial biotechnology, and nanobiotechnology.
dna

Richard (Rick) Gannotta, DHA, MBA, NP

Member of the Board of Directors

Richard Gannotta, NP, DHA, FACHE is a recognized leader in the health sector with service in CEO / President and executive roles in some of the nation’s most prominent academic and public health systems as well as a global med tech enterprise. Currently Dr Gannotta serves as the Chief Healthcare Administrative Officer at a leading health sector company and as the Senior Lecturer of Health Administration at NYU’s Robert F. Wagner Graduate School of Public Service. Previous experience includes leadership roles as CEO (and the COO prior) of the UCI Health System. Before that, he was senior vice president of hospitals at New York’s NYC Health + Hospitals, the nation’s largest public healthcare system. He also held roles as president of Chicago’s Northwestern Memorial Hospital, where he led hospital operations and worked closely with the leadership of Northwestern University’s Feinberg School of Medicine, and as president at Duke Raleigh Hospital, part of the Duke University Health System, and North Carolina-based Wake Med Health & Hospitals. Dr. Gannotta received his BSN and NP degrees from Florida International University. He earned an MBA from Campbell University, as well as his DHA from the Medical University of South Carolina, and was a Johnson & Johnson Fellow for Nurse Executives at the Wharton School of the University of Pennsylvania.
dna

Bill Stasior

Member of the Board of Directors

Bill brings years of technical experience at some of Silicon Valley’s most recognizable technology companies—most recently, as vice president of Siri, a virtual personal assistant application offered by Apple Inc. Previously, he worked as the president at A9, director of search and navigation at Amazon, director of advanced development at AltaVista, VP of engineering at AlterEgo Networks, director of development at Post Communications. His background includes research positions at the Massachusetts Institute of Technology (MIT) and the Charles Stark Draper Laboratory while earning his undergrad and doctorate degrees in Electrical Engineering and Computer Science from MIT. Bill will cultivate Avellino’s genetic data management infrastructure to support the company’s growth and expanded applications of its technologies in health and precision medicine. This, in turn, will drive industry and life-changing findings through the analysis of genetic data via artificial intelligence engines and applications.
dna

Murat Sönmez

Member of the Board of Directors

Murat Sönmez is an innovative, inspirational and purpose driven global business leader with deep technology experience in Silicon Valley complemented with more than six years as a member of the Managing Board of the World Economic Forum (WEF). In February 2017, he established and led WEF’s Centre for the Fourth Industrial Revolution (C4IR) headquartered in San Francisco, California. C4IR is a pioneering global public private partnership platform to co-design and pilot forward-looking governance protocols of the fourth industrial revolution technologies. Murat has also pioneered the concept of the data economy; a concept being piloted in multiple jurisdictions around the world. Prior to joining the WEF, Murat was a co-founder of TIBCO Software, a real-time data distribution and predictive analytics company headquartered in Palo Alto, California. TIBCO’s innovative products were adopted by internet pioneers (Amazon, eBay, Yahoo!) and global businesses in various sectors. Murat has a Bachelor of Science degree in Industrial Engineering from Bosphorus University, Istanbul, Turkey, and a Master of Science in Industrial Engineering and Operations Research from Virginia Tech.
dna

Elizabeth Yeu, MD

Member of the Board of Directors

A board-certified physician, Dr. Yeu is a nationally recognized leader and influential physician and educator in the eye care industry. She is a leading expert and lecturer, frequently speaking on the topics of refractive corneal and cataract surgery, ocular surface disease and anterior segment reconstruction and is the author of hundreds of medical articles. As an Executive Committee member of Virginia Eye Consultants, Dr. Yeu is actively involved in clinical research of new technologies and therapies to enhance patient vision and overall ocular health and is committed to exceptional patient outcomes by incorporating novel therapeutics and advanced surgical techniques. She is also Chief Medical Advisor and member of the Board of Directors at Tarsus Pharmaceuticals, serves as a Director of the Board for both STAAR Surgical and Ocular Science, and is the Chief Strategic Advisor for ACE Vision Group. Dr. Yeu earned her Bachelor of Science and her M.D. from an accelerated academic program through the University of Florida, Gainesville and the UF College of Medicine. She completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident. Dr. Yeu then went to the Cullen Eye Institute, Baylor College of Medicine to complete a Fellowship in Cornea, Anterior Segment and Refractive Surgery where she served as an Assistant Professor until 2013. She continues her commitment to residency training in ophthalmology as an Assistant Professor at the Eastern Virginia Medical School. She is the Medical Director at the Virginia Surgery Center and also sits on the Board of Directors with the Virginia Eye Foundation.

Scientific and Medical Advisory Board

dna

John Marshall

Chair of Executive Science Advisory Board

Professor John Marshall is the Frost Professor of Ophthalmology and Chairman of the Academic Department of Ophthalmology at St. Thomas’ Hospital, and was formerly Sembal Professor of Experimental Ophthalmology at the Institute of Ophthalmology from 1982-1991. His research over the past 40 years has ranged over a number of ocular problems but has concentrated on the inter-relationships between light and aging, the mechanisms underlying age-related, diabetic, and inherited retinal disease, and the development of lasers for use in ophthalmic diagnosis and surgery. This work has resulted in almost 400 research papers and numerous book chapters and books, and produced and patented the revolutionary excimer laser for the correction of refractive disorders, with excess of 17 million procedures having been undertaken worldwide. His research has also created the world’s first diode laser for treating eye problems of diabetes, glaucoma, and aging. He is editor and co-editor of numerous international journals. He has been awarded the Nettleship Medal of the Ophthalmological Society of the United Kingdom, the Mackenzie Medal, the Raynor Medal, the Ridley Medal, the Ashton Medal, the Ida Mann Medal and the Lord Crook Gold Medal of the Worshipful Company of Spectacle Makers, the Doyne Medal of the Oxford Congress, the Barraquer Medal of the International Society of Cataract and Refractive Surgery, the Kelman Innovator Award of the American Society for Refractive and Cataract Surgery, and the Lim Medal of the Singapore National Eye Centre. He has been visiting professor at numerous universities on every continent. He has held posts chairing the medical advisory boards of many international companies and was a director of Diomed for some years, this being the leading supplier of diode laser systems for surgery.
dna

Eung Kweon Kim, MD, PhD

Dr Kim is distinguished professor and Department Chairman in Ophthalmology at Yonsei University College of Medicine and Ophthalmologist at Severance Hospital in Yonsei University Health System, Seoul, Korea. Dr Kim is recognized globally for his expertise in granular corneal dystrophy, with over 140 authored peer-reviewed manuscripts on his research. He was the first to report Avellino Corneal Dystrophy (GCD2) as a contraindication to LASIK and subsequently that LASEK and PRK are also contraindicated. Dr Kim performed molecular cell biology experiments about GCD2 and reported that the fibroblast from the cornea with GCD2 is suffering from oxidative stress. He is currently researching the pathophysiology of GCD2.
dna

Terry Kim, MD

Dr Kim, Professor of Ophthalmology at Duke University Eye Center, received his medical degree from Duke University School of Medicine and completed his residency and chief residency in ophthalmology at Emory Eye Center. He continued with his fellowship training in Cornea, External Disease, and Refractive Surgery at Wills Eye Hospital. He was then recruited to Duke University Eye Center, where he serves as principal and co-investigator on a number of clinical trials and research grants from the National Institutes of Health and other industry sponsors. Dr Kim was formerly the Director of the Residency Program and Ophthalmology Fellowship Program and currently serves as Chief of the Cornea and External Disease Division and Director of the Refractive Surgery Service. Dr Kim’s clinical and surgical expertise has resulted in continual annual listings by Best Doctors in America, Best Doctors in North Carolina, and America’s Top Ophthalmologists since 2003 as well as featured stories on the Discovery Channel and The Wall Street Journal. He has also been voted by his peers as one of 300 Premier Surgeons in Ocular Surgery News. His academic accomplishments include over 300 peer-reviewed journal articles, textbook chapters, and scientific abstracts. He is also editor and author of 4 well-respected textbooks on corneal diseases and cataract surgery.
dna

Anthony J. Aldave, MD

Dr Aldave holds the Walton Li Chair in Cornea and Uveitis and is Chief of the Cornea and Uveitis Division and Director of the Cornea and Refractive Surgery Fellowship Program at the Jules Stein Eye Institute, The University of California, Los Angeles. Dr Aldave has received numerous honors during his career, including the Alpha Omega Alpha Scholarship Award for graduating first in his medical school class, the Heed Ophthalmic Foundation Fellowship, the American Ophthalmological Society-Knapp Testimonial Fund Fellowship, the first Claes Dohlman Society Award, and the Achievement, Secretariat, and Senior Achievement Awards from the American Academy of Ophthalmology. In addition to his busy clinical practice, Dr Aldave directs the Corneal Genetics Laboratory at the Jules Stein Eye Institute. Dr Aldave’s NIH-funded laboratory research focuses on the molecular genetics of the corneal dystrophies, a group of inherited disorders that affect corneal clarity and constitute one of the primary indications for corneal transplantation. Recognized as a leader in his chosen field of scientific investigation, Dr Aldave has authored over 100 peer-reviewed manuscripts, has been invited to give more than 250 scientific presentations at local, national, and international meetings, and serves as a scientific reviewer for 14 ophthalmology and genetics journals.
dna

H. Burkhard Dick, MD, PhD

Professor Dick is an international leading ophthalmologic surgeon hailing from Germany and specializing in ophthalmic viscosurgical devices. Throughout his career, he has covered the full spectrum of ophthalmologic surgeries, and regularly performs cataract surgeries, LASIK procedures, phakic IOL implantations, glaucoma operations, corneal transplants, and pars plana vitrectomies. He performs 2,500 anterior segments annually, as well as several hundred vitreoretinal surgeries. After graduating in 1983, Professor Dick spent his subsequent 2 years as Medical Officer in the German Army. He received his Doctorship in 1991, which was followed by a 2-year residency at the University Eye Hospital in Giessen. His surgical career began with his fellowship at Justus-Liebig-University Giessen Eye Hospital. Professor Dick is a member of Optical Express International Medical Advisory Board (IMAB), as well as Professor of Ophthalmology, Chairman, and Head of the University Eye Clinic Bochum. He teaches, instructs, and educates young ophthalmic surgeons in cataract and refractive procedures as well as in glaucoma and retinal surgeries. The University Eye Clinic serves as a reference center for Micro Incision Cataract Surgery (MICS) and phakic intraocular lenses. He is the author of several books and more than 300 articles in such journals as Ophthalmology, American Journal of Ophthalmology, Journal of Glaucoma, Retina, Journal of Refractive Surgery, Graefe’s Archive for Clinical and Experimental Ophthalmology, and the Journal of Cataract and Refractive Surgery. Professor Dick has also presented at numerous international conferences.
dna

Shigeru Kinoshita, MD, PhD

Professor Kinoshita graduated from Osaka University Medical School in 1974 and has served as the Professor and Chairman of Ophthalmology at Kyoto Prefectural University of Medicine since 1992. In the early 1980s, he collaborated with Dr Richard A. Toft at The Schepens Eye Research Institute in Boston and completed a cornea fellowship at Harvard Medical School. He is known in the global ophthalmic community for his groundbreaking and innovative research concerning the cornea. Professor Kinoshita will help guide the company’s research efforts to develop genetics-based personalized medicine solutions to diagnose and treat corneal dystrophies, a leading cause of visual impairment that affects more than 900 million people in the developed world and accounts for roughly half of the keratoplasty, or corneal transplant, surgeries performed today.
dna

David G. Hwang, MD, FACS

Dr Hwang is Professor and Vice Chair in the Department of Ophthalmology at the University of California, San Francisco (UCSF) and holds the Pearl T. and Samuel J. Kimura Endowed Chair in Ophthalmology. After graduating first in his medical school class at UCSF at age 20, he underwent residency training in internal medicine and ophthalmology at UCSF. He undertook fellowships in cornea, refractive surgery, and uveitis at the Doheny Eye Institute as a Heed Fellow, and he was later named one of 3 national recipients of the Heed-Knapp Fellowship. Dr Hwang joined the UCSF medical school faculty and is currently Professor and Vice Chair, Director of the Cornea Service, and Director of the Refractive Surgery Service. At UCSF, he has served as Medical Director of Ophthalmology, Director of the UCSF Eye Bank, and Vice Chair of Surgical Services. He has been elected President of the Ocular Microbiology and Immunology Group and Executive Director of the Max Fine Cornea Society. He has won the Hogan Award, the Asbury Award, the UCSF Teaching Award in Ophthalmology, the AAO Honor Award, and the AAO Senior Honor Award. He has taught over 75 clinical and postdoctoral fellows, including current professors of ophthalmology, divisional chiefs, and chairs of ophthalmology departments worldwide. He has delivered 13 named lectures and keynote addresses, published over 100 articles and scientific abstracts, and co-authored 2 texts in cornea and refractive surgery. Named one of the “Best Doctors in America” for more than 20 consecutive years, Dr Hwang’s research interests include ophthalmic antimicrobial therapy and drug resistance, corneal endothelial cell transplantation and gene transfer, and clinical development of new techniques and instrumentation in corneal, cataract, and refractive surgery.
dna

Eric Donnenfeld, MD

Dr Donnenfeld is a past president of the American Society of Cataract and Refractive Surgery and national medical director for TLC Laser Eye Centers. A clinical professor of ophthalmology at New York University Medical Center and chief medical editor of EyeWorld, Dr Donnenfeld is a well-respected researcher and innovator in ophthalmology with a specific focus in refractive surgery and an extensive body of published work. Dr Donnenfeld is a Fellow of the American Academy of Ophthalmology and practices at Ophthalmic Consultants of Long Island.
dna

Edward Holland, MD

Dr Holland is the director of cornea services at Cincinnati Eye Institute and professor of ophthalmology at the University of Cincinnati. He is a past president of the American Society of Cataract and Refractive Surgery, the Cornea Society, and the Eye Bank Association of America. Dr Holland is a recipient of the prestigious Binkhorst Medal (2008) and served on the Board of Trustees of the American Academy of Ophthalmology.
dna

Richard L. Lindstrom, MD

Dr Lindstrom is founder of Minnesota Eye Consultants, an internationally recognized leader in corneal, cataract, and refractive surgery, and sought-after keynote and guest lecturer before professional societies around the world. Known as a pioneer on the forefront of innovation in ophthalmology, Dr Lindstrom holds more than 40 patents for pharmaceuticals and medical devices that are used in clinical practices globally and has made significant contributions to the science of ophthalmology through his published clinical research.
dna

Andrea Cusumano, MD, PhD

Professor Cusumano is Research Professor of Ophthalmology at the University of Rome Tor Vergata (Italy). As a researcher of the Alexander von-Humboldt Foundation, he directed the Alfred Krupp Electron Microscopy Lab of the Eye Clinic at the Friedrich-Wilhelms University in Bonn. As a surgeon and medical scientist expert in ultrastructural analysis of the eye, he is actively contributing to the development of groundbreaking diagnostic techniques as well as to the introduction of new surgical and laser procedures for the treatment of hereditary eye diseases. Professor Cusumano is Founder and President of the Macula & Genoma Foundation Onlus, a worldwide non-profit organization supporting translational medicine in the field of ophthalmology.
dna

Vance Thompson, MD

Dr Thompson is a board-certified ophthalmologist and professor of ophthalmology at the Sanford USD School of Medicine. Dr Thompson earned his Doctorate of Medicine at the University of South Dakota’s School of Medicine and completed his residency at the University of Missouri/Columbia.With more than 25 years of experience, Dr Thompson has performed more than 75,000 vision correction surgeries worldwide and remains among a select group of refractive and cataract surgeons who prioritize the use of innovative, advanced surgical techniques. As a leading international researcher, Dr Thompson has played an important role in the discovery and development of the advanced technologies and techniques used in both laser and implant vision correction surgeries.Serving as the medical monitor lead, or principal investigator, Dr Thompson has led over 65 FDA-monitored clinical trials and has published numerous papers and book chapters on his findings. He is a fellow of the American College of Surgeons, and practices in Sioux Falls, SD.
dna

Aaron Lech, OD

Dr Lech is a graduate from the Illinois College of Optometry and holds a degree in biology from UC San Diego. He served as an eye doctor in the Navy and practiced at the Balboa Naval Hospital in San Diego, CA. While there, he was the director for both the Optometry Clinic and Specialty Contact Lens Services clinic. In 2004 he relocated to Roseville, CA where he opened ClearVue Eye Care. Dr Lech pursued optometry because, “I wanted a profession that allowed me to care for people, impact healthcare in the third world, and devote myself to my family.” Dr Lech is deeply involved in iCareforIndia, an organization dedicated to eye care and other critical healthcare services to some of the world’s most distant and in-need populations.
dna

Elizabeth Yeu, MD

A board-certified physician, Dr. Yeu is a nationally recognized leader and influential physician and educator in the eye care industry. She is a leading expert and lecturer, frequently speaking on the topics of refractive corneal and cataract surgery, ocular surface disease and anterior segment reconstruction and is the author of hundreds of medical articles. As an Executive Committee member of Virginia Eye Consultants, Dr. Yeu is actively involved in clinical research of new technologies and therapies to enhance patient vision and overall ocular health and is committed to exceptional patient outcomes by incorporating novel therapeutics and advanced surgical techniques. She is also Chief Medical Advisor and member of the Board of Directors at Tarsus Pharmaceuticals, serves as a Director of the Board for both STAAR Surgical and Ocular Science, and is the Chief Strategic Advisor for ACE Vision Group. Dr. Yeu earned her Bachelor of Science and her M.D. from an accelerated academic program through the University of Florida, Gainesville and the UF College of Medicine. She completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident. Dr. Yeu then went to the Cullen Eye Institute, Baylor College of Medicine to complete a Fellowship in Cornea, Anterior Segment and Refractive Surgery where she served as an Assistant Professor until 2013. She continues her commitment to residency training in ophthalmology as an Assistant Professor at the Eastern Virginia Medical School. She is the Medical Director at the Virginia Surgery Center and also sits on the Board of Directors with the Virginia Eye Foundation.

Executive Advisory Committee

dna

Sanford (Sandy) Climan

President, Entertainment Media Ventures, Inc., Advisor for various organizations including Pegasus Capital Advisors, L.P., Imagination Entertainment Limited, Ejamming, Wi Harper Group, World Economic Forum, and the Center For Health and The Global Environment Sandy is the President of Entertainment Media Ventures, which he founded in 1999. He previously served as part of the senior management at Creative Artists Agency for 12 years, and was the founder of CAA’s corporate practice. He has held senior executive roles across the entertainment industry, including Corporate Executive Vice President and President of Worldwide Business Development for Universal Studios, executive positions in production and distribution for MGM, and the first CEO of 3D filmmaking pioneer 3ality Digital. His productions include “U2 3D,” the first digital live-action 3D film, and “The Aviator,” starring Leonardo DiCaprio and directed by Martin Scorsese,for which he was awarded a Golden Globe and a British Academy Award. Sandy is also actively engaged in creating ventures in the areas of health and wellness. He launched sleep data company SleepScore Labs in 2016, has served on the Advisory Committee to the Director of the CDC, and serves on the board of the UCLA Longevity Center.
dna

Robert (Bob) Sikorski, MD, PhD

Managing Director, Woodside Way Ventures, Former Organizations: Five Prime Therapeutics, Medimmune, Amgen, Genzyme, Mednav, Inc. Dr Sikorski is an independent drug developer focusing on advancing next-generation therapeutics through his company Woodside Way Ventures. Previously, as the Chief Medical Officer of FivePrime Therapeutics, he built a development organization, led clinical programs that advanced oncology drugs, and led the steering committee that managed a $350 million partnership agreement with BMS. As a Senior Director of Global Oncology Research and Development at Medimmune, he managed a clinical portfolio of 6 protein-based therapeutics in Phase l and ll clinical trials. They developed the initial PDL1 x CTLA4 combination regimen that advanced to a Phase III in lung cancer. As a Director of Global Oncology Research and Development at Amgen, he was instrumental in advancing a successful pivotal Phase III trial for Vectibix that gained European Marketing Authorization based on the first gene mutation companion diagnostic in colorectal cancer. Bob was also a medical affairs advisor to Genzyme and a CTO at Mednav, Inc. He is board-certified in both oncology and internal medicine. He has served as an editor for Science magazine and the Journal of the American Medical Association.
dna

Jonathan (Jack) Lord, MD

Chief Operating Officer of the Miller School and Uhealth-University Of Miami Health System Dr Lord currently serves as the Chair of the Board of Directors of Dexcom, as a Director at Stericycle, and serves on advisory boards for Serco PLC (UK), Anthelio Health, and Third Rock Ventures. He has earned certificates in Governance and Audit from the Harvard Business School. A nationally recognized leader in innovations in healthcare, Dr Lord became the University of Miami’s Chief Innovation Officer when he returned to his alma mater in September 2011, after 3 decades in healthcare leadership roles. In March 2012, he was named Chief Operating Officer of the Miller School of Medicine and UHealth-University of Miami Health System. He completed a financial turnaround of the Miller School and continues to serve today as a Professor of Pathology. A board-certified forensic pathologist who began his medical career in the US Navy and later served as Chief Operating Officer of the American Hospital Association and several biotech companies, Dr Lord served as the CEO for Navigenics, Inc., following his tenure as the former Chief Innovation Officer and senior vice president of Humana. During his time at Humana, he created Humana’s Innovation Center, which combines research, technology, and consumer experience to promote health and well-being.
dna

Jeffrey (Jeff) Finer, MD, PhD

Chairman, Dexcom, Inc. Venture Partner, Third Rock Ventures, Former Organizations: Theravance Biopharma,Inc., Five Prime Therapeutics, Cytokinetics Dr Finer brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives, preclinical development, and translational medicine. Prior to joining Third Rock, Dr Finer spent many years in R&D leadership positions at several biotechnology companies. From 2007 to 2011, Dr Finer was Vice President, Discovery at Five Prime Therapeutics, and he served as Director, Drug Discovery Technologies at Cytokinetics after helping launch the company in 1998. Dr Finer has focused his career on breakthrough innovations that have included moving several first-in-class drugs into the clinic and developing novel technology platforms that integrate science, instruments, and informatics. He holds several patents and he has published extensively in peer-reviewed journals. Dr Finer obtained his MD and PhD in Biochemistry from Stanford University School of Medicine, and he holds BS degrees in Chemistry and Biology from Massachusetts Institute of Technology (MIT).

Read our latest press releases

Talk to us about possibilities and partnerships